Royalty Pharma inks MS deal with ImmuNext; X4 sells its priority review voucher

Plus, news about Pacira Biosciences, Cassava Sciences, Merck, Monopar Therapeutics, Eli Lilly and Optinose:

Royalty Pharma signs MS deal: The company will pay about $525 million in cash to buy the milestones and royalties that ImmuNext is set to receive from Sanofi for a Phase 3 multiple sclerosis drug. Sanofi is expected to seek FDA approval of the monoclonal antibody in 2027. If frexalimab is approved, Royalty expects to get royalties from the drug through 2041. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Feds killed plan to curb Medicare Advantage overbilling after industry opposition

A decade ago, federal officials drafted a plan to discourage Medicare Advantage health insurers from overcharging the government by billions of dollars — only to

August 27, 2024

Novel Biannual Antihypertensive Shows Potential for Combination Therapy

ATLANTA — The novel RNA silencer zilebesiran reduced blood pressure (BP) when added to a diuretic, calcium channel blocker, or maximum-dose angiotensin receptor blocker, the

April 10, 2024

CDC: Cases of MIS-C After COVID Still Occurring in U.S. Kids

Cases of multisystem inflammatory syndrome in children (MIS-C) are still popping up, but at lower rates than those observed early in the COVID-19 pandemic, CDC

March 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.